US equities |
NVDA $240.80 ▲+0.80% SPCX $173.73 ▲+1.54% MU $1,066.04 ▲+0.20% MRVL $287.33 ▲+5.93% AMD $655.57 ▲+3.77% SNDK $1,674.39 ▼-1.75% AVGO $378.46 ▲+4.40% INTC $113.27 ▼-2.51%
FinancialContent

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.380 -0.150 (-5.93%)
Delayed Quote Updated: 12:32 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance ↗
Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including... 
Via MarketBeat
News headline image
Nkarta to Participate in September Investor Conferences
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances ↗
Via Chartmill
News headline image
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
From Cyllene Therapeutics
Via GlobeNewswire
News headline image
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From Nkarta, Inc.
Via GlobeNewswire
News headline image
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
From Equity Insider
Via GlobeNewswire
News headline image
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
From Biotech Insider
Via GlobeNewswire
News headline image
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in Needham Virtual Healthcare Conference
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in March Investor Conferences
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in Evercore Healthcare Conference
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta to Participate in November Investor Conferences
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
From Nkarta, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Nkarta Posts Narrower Loss in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space ↗
Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and market position. 
Via Benzinga
News headline image
This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Top movers in Thursday's session ↗
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Top stock movements in today's session. ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? ↗
Nkarta restructures to extend its cash runway into 2029, with upcoming NKX019 clinical data readouts in H2 2025. Analysts maintain Buy ratings. 
Via Benzinga
News headline image
Which stocks are gapping on Thursday? ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >